Getein Biotech, Inc (SHA:603387)

Market Cap	4.08B
Revenue (ttm)	1.25B
Net Income (ttm)	252.99M
Shares Out	507.15M
EPS (ttm)	0.50
PE Ratio	16.09
Forward PE	n/a
Dividend	0.18 (2.25%)
Ex-Dividend Date	n/a

Volume	3,928,821
Average Volume	5,137,576
Open	8.00
Previous Close	8.00
Day's Range	7.99 - 8.14
52-Week Range	6.93 - 10.09
Beta	0.34
RSI	44.51
Earnings Date	Apr 30, 2025

About Getein Biotech

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection of cardiac troponin I, chemiluminescence, biochemical detection, molecular detection, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical immunity, thrombosis and hemostasis, and other technical fields, covering cardiovascular, inflammation, kidney, thyroid function, hormon...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2002
• Employees: 2,508
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603387

Financial Performance

In 2023, Getein Biotech's revenue was 1.37 billion, a decrease of -24.85% compared to the previous year's 1.82 billion. Earnings were 279.77 million, a decrease of -43.92%.